Based on its strong deal experience with biotech and pharmaceutical transactions especially in the cross-border area, Han Yi team has recently helped The Carlyle Group successfully acquire a strategic minority position in Ambio Holdings, Inc. ("Ambio Pharm").

Ambio Pharm is a rapidly growing U.S.-based contract development and manufacturing firm for peptide active pharmaceutical ingredients/APIs, with production bases located in both China and the U.S. It's primarily engaged in contract development and manufacturing of peptide APIs for drugs authorized by FDAs in the U.S., the EU and China, and also actively cooperates with quite a few leading global pharmaceutical firms on the development and manufacturing of generic peptides.

As Carlyle's PRC counsel, Han Yi team run a customary PRC legal due diligence review, investigation and report, reviewed and assisted with revisions of all transaction agreements and provided PRC legal advisory support through completion of the closing.